elizabeth loder, md, professor of neurology, harvard medical school; chief, division of headache, brigham & women's hospital.
.
advertisement
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
. feedback to editors
.
.
add your comments
.
the situation has become so bad that a cross-party committee of politicians called it a
.experts say years of cuts to nhs budgets and staff has led to patients waiting longer for chemotherapy and radiotherapy (file pic)
.